Head-to-head comparison of Rezum vs Urolift for patient with benign prostatic hyperplasia: A systematic review
Abstract
Introduction: Minimally invasive surgical therapies (MISTs) have been developed to treat Benign Prostatic hyperplasia (BPH) while minimizing adverse surgical effect. Most recent developed MIST, Rezum and Urolift, showed effective efficacy in improving, but head-to-head comparison still lacking. This study aims to compare the efficacy and safety of Urolift and Rezum in managing BPH-related LUTS.
Methods:A systematic search was conducted in Cochrane, PubMed, EMBASE, SCOPUS and EBSCOhost, identifying observational studies comparing rezum and urolift in BPH patient. Data extraction included demographics, intervention protocols, follow-up duration, and outcomes International Prostate Symptom Score (IPSS) score, IPSS-QoL, sexual function, and reintervention rate. The quality of studies was assessed using the Newcastle-Ottawa Scale.
Results:Two cohort with a total of 101 patients with BPH were included. At 12 months, Rezum tends to be superior in improving symptoms severity, while at 2 months of follow-up, Urolift outperformed Rezum. Both intervention preserved patient’s sexual function and does not differ significantly. Reintervention rate significantly higher in Urolift compared to Rezum group.
Conclusion: Rezum offers a more effective alternative to Urolift for managing BPH in long term setting, with lower reintervention rate and preserved sexual function. In early setting, Urolift showed higher efficacy and rapid improvement compared to Rezum.
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 101 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.